Biology Matters: Solving Chronic Disease

Fame Host (https://fame.so) Biology Matters: Solving Chronic Disease https://podcasts.fame.so/biology-matters https://feeds.fame.so/biology-matters Biology Matters is a podcast about one of the biggest challenges facing modern healthcare: chronic disease. These conditions affect billions of people, account for the majority of healthcare spending, and yet remain poorly understood, difficult to diagnose, and often ineffective to treat. The result is not just a scientific problem, but a system-wide healthcare crisis. Hosted by Steve and Rowan Gardner of PrecisionLife, the podcast takes a different approach - starting with biology. Through conversations with healthcare executives, researchers, biotech leaders and patient advocates, Biology Matters explores how a deeper, mechanism-based understanding of disease can transform how we predict risk, stratify patients, and make better clinical and development decisions. Each episode connects biological insight to real-world impact - from improving patient outcomes and reducing system inefficiencies, to enabling more successful clinical trials and more precise treatment strategies. If healthcare is to move from reactive treatment to predictive, preventative, and personalized care, it will require a fundamental shift in how we understand disease. This podcast is about what that shift looks like—and what it will take to make it happen. To find out more about PrecisionLife, visit precisionlife.com and follow @PrecisionLife on LinkedIn. Copyrights © 2026 All Rights Reserved by PrecisionLife en Tue, 26 May 2026 14:44:55 +0000 Wed, 16 Sep 2026 02:30:08 +0000 https://content.fameapp.so/uploads/65qwlx91/c8b55850-9c72-11f1-ac7a-c75e56401aa4/c8b55ab0-9c72-11f1-8481-2f128f3eb9be.png Biology Matters: Solving Chronic Disease https://podcasts.fame.so/biology-matters Biology Matters is a podcast about one of the biggest challenges facing modern healthcare: chronic disease. These conditions affect billions of people, account for the majority of healthcare spending, and yet remain poorly understood, difficult to diagnose, and often ineffective to treat. The result is not just a scientific problem, but a system-wide healthcare crisis. Hosted by Steve and Rowan Gardner of PrecisionLife, the podcast takes a different approach - starting with biology. Through conversations with healthcare executives, researchers, biotech leaders and patient advocates, Biology Matters explores how a deeper, mechanism-based understanding of disease can transform how we predict risk, stratify patients, and make better clinical and development decisions. Each episode connects biological insight to real-world impact - from improving patient outcomes and reducing system inefficiencies, to enabling more successful clinical trials and more precise treatment strategies. If healthcare is to move from reactive treatment to predictive, preventative, and personalized care, it will require a fundamental shift in how we understand disease. This podcast is about what that shift looks like—and what it will take to make it happen. To find out more about PrecisionLife, visit precisionlife.com and follow @PrecisionLife on LinkedIn. PrecisionLife Biology Matters is a podcast about one of the biggest challenges facing modern healthcare: chronic disease. These conditions affect billions of people, account for the majority of healthcare spending, and yet remain poorly understood, difficult to diagnose, and often ineffective to treat. The result is not just a scientific problem, but a system-wide healthcare crisis. Hosted by Steve and Rowan Gardner of PrecisionLife, the podcast takes a different approach - starting with biology. Through conversations with healthcare executives, researchers, biotech leaders and patient advocates, Biology Matters explores how a deeper, mechanism-based understanding of disease can transform how we predict risk, stratify patients, and make better clinical and development decisions. Each episode connects biological insight to real-world impact - from improving patient outcomes and reducing system inefficiencies, to enabling more successful clinical trials and more precise treatment strategies. If healthcare is to move from reactive treatment to predictive, preventative, and personalized care, it will require a fundamental shift in how we understand disease. This podcast is about what that shift looks like—and what it will take to make it happen. To find out more about PrecisionLife, visit precisionlife.com and follow @PrecisionLife on LinkedIn. No No episodic PrecisionLife Biology Matters is a podcast about one of the biggest challenges facing modern healthcare: chronic disease. These conditions affect billions of people, account for the majority of healthcare spending, and yet remain poorly understood, difficult to diagnose, and often ineffective to treat. The result is not just a scientific problem, but a system-wide healthcare crisis. Hosted by Steve and Rowan Gardner of PrecisionLife, the podcast takes a different approach - starting with biology. Through conversations with healthcare executives, researchers, biotech leaders and patient advocates, Biology Matters explores how a deeper, mechanism-based understanding of disease can transform how we predict risk, stratify patients, and make better clinical and development decisions. Each episode connects biological insight to real-world impact - from improving patient outcomes and reducing system inefficiencies, to enabling more successful clinical trials and more precise treatment strategies. If healthcare is to move from reactive treatment to predictive, preventative, and personalized care, it will require a fundamental shift in how we understand disease. This podcast is about what that shift looks like—and what it will take to make it happen. To find out more about PrecisionLife, visit precisionlife.com and follow @PrecisionLife on LinkedIn. Biology Matters is a podcast about one of the biggest challenges facing modern healthcare: chronic disease. These conditions affect billions of people, account for the majority of healthcare spending, and yet remain poorly understood, difficult to diagnose, and often ineffective to treat. The result is not just a scientific problem, but a system-wide healthcare crisis. Hosted by Steve and Rowan Gardner of PrecisionLife, the podcast takes a different approach - starting with biology. Through conversations with healthcare executives, researchers, biotech leaders and patient advocates, Biology Matters explores how a deeper, mechanism-based understanding of disease can transform how we predict risk, stratify patients, and make better clinical and development decisions. Each episode connects biological insight to real-world impact - from improving patient outcomes and reducing system inefficiencies, to enabling more successful clinical trials and more precise treatment strategies. If healthcare is to move from reactive treatment to predictive, preventative, and personalized care, it will require a fundamental shift in how we understand disease. This podcast is about what that shift looks like—and what it will take to make it happen. To find out more about PrecisionLife, visit precisionlife.com and follow @PrecisionLife on LinkedIn. biology matters podcast, chronic disease podcast, precision medicine podcast, healthcare innovation podcast, disease biology podcast, life sciences podcast, biomedical research podcast, future of healthcare podcast, healthcare transformation podcast, medi Steve Gardner team-plf@fame.so No No No The $100 Billion GLP-1 Question: Can We Predict Patient Response? https://podcasts.fame.so/e/x812rr6n-100-billion-glp-1-question The $100 Billion GLP-1 Question: Can We Predict Patient Response? 0 No No 713rzz70 If we can understand which biological mechanisms are driving different outcomes in different patients, how much more precise could medicine become? Take GLP-1 therapies, for example. They’re reshaping the treatment of metabolic disease, but they do not work the same way for every patient. In this episode of Biology Matters, Barry Wark, Co-Founder and Chief Strategy Officer of Ovation, breaks down why the next phase of precision medicine may depend on linking multi-omic data with longitudinal clinical outcomes. Together, they explore how real-world patient data can help researchers understand who responds to therapies, why different outcomes may be driven by different biological mechanisms and how more focused datasets could support better clinical trials, smarter payer decisions and faster translation of new insights into healthcare. The promise of precision medicine is simple to state and difficult to deliver: the right treatment, for the right patient, at the right time. One of the challenges is that researchers often lack access to biological data that can be linked to what happens to patients over time.

Barry Wark, Co-Founder and Chief Strategy Officer of Ovation, has spent much of his career working on one of the rate-limiting factors behind that promise: access to consented biospecimens that can be linked to longitudinal clinical outcomes.

In this episode of Biology Matters, Rowan Gardner speaks with Barry about how Ovation’s approach to multi-omic human biobanking is designed to meet patients where they already are in healthcare. Instead of relying only on large, all-comers biobanks or slow prospective trials, Ovation works with real-world clinical networks to connect consented samples with health records, allowing researchers to build focused disease cohorts more quickly and study how patients actually progress and respond in routine care.

What You'll Learn:

Why longitudinal clinical records can make biobanks more powerful for precision medicine
How “meeting patients where they are” can reduce friction in real-world data generation
Why GLP-1 response is a major test case for precision medicine in chronic disease
Why weight loss and blood sugar control may involve different biological mechanisms
How multi-omic data can support better patient stratification and clinical trial design
Why precision medicine should improve access to effective therapies, not restrict it
Why data sovereignty and insight portability can coexist in global precision medicine
How clinical data could create a feedback loop between research, treatment and patient outcomes

About Rowan

At PrecisionLife, Rowan focuses on how better biological understanding, patient stratification and mechanism-based insights can help healthcare move from broad diagnostic labels toward earlier diagnosis, more precise treatment selection and more effective chronic disease management.

About Barry

Barry Wark is Co-Founder and Chief Strategy Officer of Ovation, a multi-omic human biobank company focused on accelerating precision medicine through consented biospecimens linked to longitudinal clinical outcomes. He holds a degree in Symbolic Systems from Stanford University and a PhD in Neurobiology and Behavior from the University of Washington.

Barry’s work sits at the intersection of life science data, translational research and precision medicine infrastructure. His early experience in research data management showed him how much scientific value can remain locked inside disconnected datasets. That insight ultimately shaped Ovation’s mission: to make high-quality, real-world patient data available when researchers, healthcare systems and life science organizations need it.

Episode Resources:

Barry Wark on LinkedIn

Ovation Website
Rowan Gardner on LinkedIn
PrecisionLife Website

Biology Matters is handcrafted by our friends over at: fame.so

]]> Wed, 09 Sep 2026 09:00:00 +0000 PrecisionLife PrecisionLife 3429 If we can understand which biological mechanisms are driving different outcomes in different patients, how much more precise could medicine become? Take GLP-1 therapies, for example. They’re reshaping the treatment of metabolic disease, but they do not work the same way for every patient. In this episode of Biology Matters, Barry Wark, Co-Founder and Chief Strategy Officer of Ovation, breaks down why the next phase of precision medicine may depend on linking multi-omic data with longitudinal clinical outcomes. Together, they explore how real-world patient data can help researchers understand who responds to therapies, why different outcomes may be driven by different biological mechanisms and how more focused datasets could support better clinical trials, smarter payer decisions and faster translation of new insights into healthcare. If we can understand which biological mechanisms are driving different outcomes in different patients, how much more precise could medicine become? Take GLP-1 therapies, for example. They’re reshaping the treatment of metabolic disease, but they do not work the same way for every patient. In this episode of Biology Matters, Barry Wark, Co-Founder and Chief Strategy Officer of Ovation, breaks down why the next phase of precision medicine may depend on linking multi-omic data with longitudinal clinical outcomes. Together, they explore how real-world patient data can help researchers understand who responds to therapies, why different outcomes may be driven by different biological mechanisms and how more focused datasets could support better clinical trials, smarter payer decisions and faster translation of new insights into healthcare. GLP-1, precision medicine, GLP-1 therapies, real-world data, multi-omic data, chronic disease, GLP-1 response, patient stratification, longitudinal clinical outcomes, metabolic disease, treatment response, biological mechanisms, clinical data, personalized medicine, Barry Wark No No How Close are We to Precision Medicine for ME/CFS & Long COVID? ft. Chris Armstrong https://podcasts.fame.so/e/182r37k8-chris-armstrong How Close are We to Precision Medicine for ME/CFS & Long COVID? ft. Chris Armstrong 0 No No 2099znx0 ME/CFS and Long COVID are complex, multi-system conditions that have been difficult to diagnose, study and treat through traditional approaches. Yet standard trials keep failing because they treat heterogeneous patient cohorts as a single disease. In this episode of Biology Matters, PrecisionLife CEO Steve Gardner joins Chris Armstrong, Director of the Melbourne ME/CFS Collaboration and Scientific Advisor to the Open Medicine Foundation. Together, they explore how mechanistic patient stratification can break the deadlock in developing successful treatments for chronic complex diseases like long COVID and ME/CFS. Complex chronic conditions like ME/CFS and Long COVID routinely stall in clinical development. Traditional trial designs rely on broad diagnostic criteria, grouping biologically distinct patients together and drowning real drug efficacy signals in noise.

In this episode of Biology Matters, Steve Gardner speaks with Chris Armstrong, Director of the Melbourne ME/CFS Collaboration and Scientific Advisor to the Open Medicine Foundation, about how the science around it is evolving, from metabolomics and patient stratification and how precision medicine could help move the field forward.

What You'll Learn:

How Chris Armstrong first entered ME/CFS research through metabolomics
Why metabolomics can help identify biological patterns and potential disease markers
What the nitrogen hypothesis suggests about amino acid metabolism in ME/CFS
Why ME/CFS and Long COVID are unlikely to be solved by one single treatment
How patient stratification could improve clinical trial design
Why drug repurposing may offer a faster route to potential treatments
Why dosing and tolerability matter in frail or sensitive patient populations
How better biological markers could help pharma, researchers and clinicians move forward
Why the next five years could bring more useful tools and treatment insights for patients

About Steve

Steve Gardner is CEO and Co-Founder of PrecisionLife, recognised for his expertise in mechanism-based biology and its application to chronic disease management. With over 25 years of experience in life sciences and informatics, he has contributed to the Human Genome Project, led over 30 drug discovery and development initiatives, and built multiple healthcare and AI technologies from concept to market. His work bridges computational biology with clinical translation, positioning him at the forefront of precision medicine for complex chronic conditions, a space historically underserved by traditional approaches that have often focused more heavily on oncology.

At PrecisionLife, Steve focuses on using better biological understanding to support earlier diagnosis, patient stratification and more targeted treatment development.

About Chris

Chris Armstrong is Director of the Melbourne ME/CFS Collaboration and Scientific Advisor to the Open Medicine Foundation. Based at the Bio21 Molecular Science and Biotechnology Institute at the University of Melbourne, Chris has spent more than 15 years studying ME/CFS, with a particular focus on metabolomics, metabolic profiling and the biological mechanisms that may help explain the condition’s complex symptom patterns.

His research explores how metabolism, amino acid usage, nitrogen handling, heterogeneity and patient subgroups may shape ME/CFS and related conditions such as Long COVID. Chris’s work reflects a broader shift in the field: away from searching for one single explanation and toward understanding the different biological pathways that may be driving disease in different patients.

Episode Resources:

Chris Armstrong on LinkedIn
Steve Gardner on LinkedIn
PrecisionLife Website

Biology Matters is handcrafted by our friends over at: fame.so

]]> Wed, 26 Aug 2026 09:00:00 +0000 PrecisionLife PrecisionLife 3181 ME/CFS and Long COVID are complex, multi-system conditions that have been difficult to diagnose, study and treat through traditional approaches. Yet standard trials keep failing because they treat heterogeneous patient cohorts as a single disease. In this episode of Biology Matters, PrecisionLife CEO Steve Gardner joins Chris Armstrong, Director of the Melbourne ME/CFS Collaboration and Scientific Advisor to the Open Medicine Foundation. Together, they explore how mechanistic patient stratification can break the deadlock in developing successful treatments for chronic complex diseases like long COVID and ME/CFS. ME/CFS and Long COVID are complex, multi-system conditions that have been difficult to diagnose, study and treat through traditional approaches. Yet standard trials keep failing because they treat heterogeneous patient cohorts as a single disease. In this episode of Biology Matters, PrecisionLife CEO Steve Gardner joins Chris Armstrong, Director of the Melbourne ME/CFS Collaboration and Scientific Advisor to the Open Medicine Foundation. Together, they explore how mechanistic patient stratification can break the deadlock in developing successful treatments for chronic complex diseases like long COVID and ME/CFS. ME/CFS, Long COVID, Precision Medicine, Metabolomics, Patient Stratification, ME/CFS Research, Drug Repurposing, Clinical Trial Design, Chronic Disease, Metabolic Profiling, PrecisionLife, Open Medicine Foundation, Melbourne ME/CFS Collaboration, Chris Armstrong, Steve Gardner No No What’s Holding Back Women’s Health? https://podcasts.fame.so/e/q80v2pl8-what-s-holding-back-women-s-health What’s Holding Back Women’s Health? 0 No No p0knrv21 Women’s health is often discussed through the narrow lens of reproductive health. But the real scope of women’s health is much broader than that. In this episode of Biology Matters, host Rowan Gardner, Co-Founder of PrecisionLife, speaks with Chief Medical Officer, Dr. Veronique Bouchet, about why women’s health must be understood across the full spectrum of complex chronic disease. They explore why conditions ranging from cardiovascular disease and autoimmune disease to migraines, Alzheimer’s disease, and endometriosis require deeper biological understanding, better research, earlier diagnosis and more precise treatment pathways. Our healthcare systems are often working with incomplete data and this contributes to diagnostic delays. Could precision medicine help clinicians, patients, researchers, pharma and investors move toward better outcomes? Tune in to find out. Women’s health is often reduced to reproductive health, excluding the wider reality of how complex chronic diseases affect women across their lives. In this episode of Biology Matters, Rowan Gardner speaks with Dr. Veronique Bouchet, Chief Medical Officer at PrecisionLife, about the need to understand women’s health through a broader, biology-first lens. The conversation explores why diagnosis can be so difficult in overwhelmed healthcare systems, how clinicians are often working within pathways that were not designed around the complexity of women’s biology and how precision medicine can help solve the dearth of fast, accessible and non-invasive diagnostic tools that can help match patients to the right care earlier.

What You'll Learn:

Why women’s health needs rethinking beyond reproductive medicine
How common conditions such as depression, cardiovascular disease, autoimmune disease, migraine and Alzheimer’s disease affect women differently
Why diagnostic delay is common in complex women’s health conditions such as endometriosis
How incomplete biological data limits research, clinical trials and treatment development
Why investment in women’s health has historically focused on too narrow areas of care
Why better stratification can help clinicians, patients, pharma, biotech and healthcare systems move forward together

About Rowan

Rowan Gardner is Chief Business and Investment Officer and Co-Founder of Precision Life, bringing 30+ years of experience across health tech, digital health, deep tech and biotech. Her expertise spans securing venture funding, building strategic partnerships and translating breakthrough science into real-world healthcare impact across multiple continents. Her insights into what leading health systems worldwide are doing differently provide actionable guidance for clinical leaders seeking to implement mechanism-based strategies that improve outcomes while reducing healthcare costs.

About Veronique

Dr. Veronique Bouchet is Chief Medical Officer at PrecisionLife and a physician executive with more than three decades of international experience across biopharma, digital health, venture strategy and precision medicine. Her clinical background spans obstetrics, gynaecology, paediatrics and general medicine, giving her a broad view of the health challenges women face across adolescence, childbearing years, menopause and later life. Over the course of her career, Veronique has focused on translating scientific advances into practical patient impact, with a particular interest in complex chronic disease and women’s health.

Her work reflects the central belief that better understanding of biology can help healthcare move from broad symptom management toward earlier diagnosis, stratified treatment and more precise care.

Episode Resources:

Veronique Bouchet on LinkedIn
Rowan Gardner on LinkedIn
PrecisionLife Website

Biology Matters is handcrafted by our friends over at: fame.so

]]> Wed, 29 Jul 2026 09:02:00 +0000 PrecisionLife PrecisionLife 2543 Women’s health is often discussed through the narrow lens of reproductive health. But the real scope of women’s health is much broader than that. In this episode of Biology Matters, host Rowan Gardner, Co-Founder of PrecisionLife, speaks with Chief Medical Officer, Dr. Veronique Bouchet, about why women’s health must be understood across the full spectrum of complex chronic disease. They explore why conditions ranging from cardiovascular disease and autoimmune disease to migraines, Alzheimer’s disease, and endometriosis require deeper biological understanding, better research, earlier diagnosis and more precise treatment pathways. Our healthcare systems are often working with incomplete data and this contributes to diagnostic delays. Could precision medicine help clinicians, patients, researchers, pharma and investors move toward better outcomes? Tune in to find out. Women’s health is often discussed through the narrow lens of reproductive health. But the real scope of women’s health is much broader than that. In this episode of Biology Matters, host Rowan Gardner, Co-Founder of PrecisionLife, speaks with Chief Medical Officer, Dr. Veronique Bouchet, about why women’s health must be understood across the full spectrum of complex chronic disease. They explore why conditions ranging from cardiovascular disease and autoimmune disease to migraines, Alzheimer’s disease, and endometriosis require deeper biological understanding, better research, earlier diagnosis and more precise treatment pathways. Our healthcare systems are often working with incomplete data and this contributes to diagnostic delays. Could precision medicine help clinicians, patients, researchers, pharma and investors move toward better outcomes? Tune in to find out. women's health, precision medicine, women's health podcast, complex chronic disease, endometriosis, healthcare innovation, personalized medicine, Veronique Bouchet, PrecisionLife, Biology Matters podcast No No Why ME/CFS Has Been Neglected for Decades - And Why That's Finally Changing https://podcasts.fame.so/e/m84l46p8-Sonya-Chowdhury Why ME/CFS Has Been Neglected for Decades - And Why That's Finally Changing 0 No No x16r9ky1 Myalgic encephalomyelitis, also called chronic fatigue syndrome or ME/CFS, affects an estimated 17 – 24 million people worldwide, with many more experiencing ME-like symptoms after infections such as COVID. So, why does the disease remain poorly understood, difficult to diagnose and deeply isolating? In this episode of Biology Matters, host Steve Gardner speaks with Sonya Chowdhury, CEO of Action for ME, about why ME/CFS has remained invisible for so long, how patient advocacy is helping move research, policy and clinical understanding forward and why better funding, better diagnostics and precision medicine could help shift the field from recognition to real treatment options. Myalgic encephalomyelitis, also called chronic fatigue syndrome or ME/CFS, is a serious, life-altering disease that affects an estimated 17 – 24 million people worldwide, with many more living with ME-like symptoms following infections such as COVID. For patients and families, the impact can be enormous: persistent exhaustion, post-exertional malaise, pain, cognitive dysfunction, and in the most severe cases, being housebound, bedbound or unable to manage daily living tasks. And yet, awareness about what it is lags behind, let alone treatment options.

In this episode of Biology Matters, Steve Gardner speaks with Sonya Chowdhury, CEO of Action for ME, about why ME/CFS has remained so under-recognised, despite its scale and severity. Sonya explains that the disease often makes people invisible, because those most affected may be too unwell to leave their homes, attend appointments, work, study or maintain social contact. The conversation explores the importance of advocacy, collaboration and patient involvement in changing that reality.

What You'll Learn:

What ME/CFS is and why post-exertional malaise is such a defining feature of the disease
Why ME/CFS and ME-like symptoms after COVID affect such a large number of people
How invisibility and isolation shape the patient experience
Why advocacy for ME/CFS depends on listening, collaboration and persistence
How patient involvement can make research stronger and more trusted
Why the economic case for better ME/CFS research and care is so significant
How the DecodeME study, LOCOME project, and precision medicine approaches are changing what is possible
Why dedicated funding could accelerate diagnostics, drug repurposing and clinical progress

About Steve

Steve Gardner is CEO and Co-Founder of PrecisionLife, recognized for his expertise in mechanism-based biology and its application to chronic disease management. With over 25 years of experience in life sciences and informatics, he has contributed to the Human Genome Project, led over 30 drug discovery and development initiatives, and built multiple healthcare and AI technologies from concept to market. His work bridging computational biology with clinical translation has positioned him at the forefront of precision medicine for complex chronic conditions.

About Sonya

Sonya Chowdhury is CEO of Action for ME, a UK charity working to improve the lives of children, adults and families affected by myalgic encephalomyelitis, also known as ME or ME/CFS. She works at the intersection of patient advocacy, public policy, research, fundraising and healthcare, helping build understanding of ME and improve recognition of the needs of people living with the disease. Her background in child protection social work has shaped her collaborative approach to advocacy, which is grounded in listening, partnership and championing the rights of people who are facing disadvantage, inequity and injustice. Through Action for ME, Sonya has helped keep patient experience at the centre of research, policy and public awareness, while supporting efforts to improve diagnosis, care, funding and scientific understanding for ME and related post-infectious conditions.

Episode Resources:

Sonya Chowdhury on LinkedIn

Action for ME Website
Steve Gardner on LinkedIn
PrecisionLife Website

Biology Matters is handcrafted by our friends over at: fame.so

]]> Wed, 15 Jul 2026 09:00:00 +0000 PrecisionLife PrecisionLife 3431 Myalgic encephalomyelitis, also called chronic fatigue syndrome or ME/CFS, affects an estimated 17 – 24 million people worldwide, with many more experiencing ME-like symptoms after infections such as COVID. So, why does the disease remain poorly understood, difficult to diagnose and deeply isolating? In this episode of Biology Matters, host Steve Gardner speaks with Sonya Chowdhury, CEO of Action for ME, about why ME/CFS has remained invisible for so long, how patient advocacy is helping move research, policy and clinical understanding forward and why better funding, better diagnostics and precision medicine could help shift the field from recognition to real treatment options. Myalgic encephalomyelitis, also called chronic fatigue syndrome or ME/CFS, affects an estimated 17 – 24 million people worldwide, with many more experiencing ME-like symptoms after infections such as COVID. So, why does the disease remain poorly understood, difficult to diagnose and deeply isolating? In this episode of Biology Matters, host Steve Gardner speaks with Sonya Chowdhury, CEO of Action for ME, about why ME/CFS has remained invisible for so long, how patient advocacy is helping move research, policy and clinical understanding forward and why better funding, better diagnostics and precision medicine could help shift the field from recognition to real treatment options. Myalgic Encephalomyelitis, ME/CFS, Chronic Fatigue Syndrome, Precision Medicine, Long COVID, Post-Exertional Malaise, Chronic Disease Research, Patient Advocacy, ME Research Funding, ME Diagnosis No No How Healthcare Moves from Reactive Care to Preventive with Ray Pawlicki https://podcasts.fame.so/e/5nz74738-ray-pawlicki How Healthcare Moves from Reactive Care to Preventive with Ray Pawlicki 0 No No 80zn6n50 Healthcare systems all around the world are under pressure, and the common denominator is chronic disease. In this episode of Biology Matters, Ray Pawlicki, Executive Chairman at PrecisionLife, and host Steve Gardner explore how a shift from reacting to illness toward diagnosing, treating, and preventing disease much earlier is the solution we need to relieve this pressure. Drawing on decades of leadership experience across Novartis, Biogen, UMass Memorial Health, and beyond, Ray explains why technology is now a strategic priority in healthcare, why culture matters just as much as data, and why solving chronic disease will require new thinking on the part of providers, payers, patients, and healthcare leaders alike. Healthcare systems around the world are facing a difficult reality: more people are living longer, but with multiple chronic diseases that are expensive, difficult to manage, and usually diagnosed too late. In this episode of Biology Matters, Ray Pawlicki, Executive Chairman at PrecisionLife, and host Steve Gardner, unpack why this isn’t just a medical challenge but a technology, leadership, and culture challenge.

What You'll Learn:

The distinct hurdles healthcare faces compared to other industries when adopting technology.
How culture, leadership, and communication shape successful healthcare transformation
Why chronic disease is one of the biggest drivers of healthcare spending and system pressure
Why earlier diagnosis and disease-modifying therapies are essential for long-term health
Where AI can genuinely help healthcare (and where it cannot replace biological understanding)
Why the future of healthcare depends on moving from reactive treatment to precision prevention

About Ray

Ray Pawlicki is Executive Chairman at PrecisionLife and a technology leader with decades of experience across life sciences, healthcare, consumer goods, financial services, and technology. He has held senior leadership roles at organizations including Novartis, Biogen, UMass Memorial Health, PepsiCo, Citibank, and Hewlett Packard.

Over the course of his career, he has worked closely with leadership to make technology and data central to the company’s transformation and lead major culture-change initiatives designed to support more collaborative, science-led, and data-driven ways of working. Today, Ray brings this cross-industry perspective to PrecisionLife, where he focuses on how technology, data, and precision medicine can help healthcare systems diagnose disease earlier, treat patients more effectively, and shift toward prevention.

About Steve

Steve Gardner is CEO and Co-Founder of Precision Life, recognized for his expertise in mechanism-based biology and its application to chronic disease management. With over 25 years of experience in life sciences and informatics, he has contributed to the Human Genome Project, led over 30 drug discovery and development initiatives, and built multiple healthcare and AI technologies from concept to market. His work bridging computational biology with clinical translation has positioned him at the forefront of precision medicine for complex chronic conditions - a space historically overlooked in favor of oncology-focused approaches.

Episode Resources:

Ray Pawlicki on LinkedIn

Steve Gardner on LinkedIn
PrecisionLife Website

Biology Matters is handcrafted by our friends over at: fame.so

]]> Wed, 01 Jul 2026 09:00:00 +0000 PrecisionLife PrecisionLife 2924 Healthcare systems all around the world are under pressure, and the common denominator is chronic disease. In this episode of Biology Matters, Ray Pawlicki, Executive Chairman at PrecisionLife, and host Steve Gardner explore how a shift from reacting to illness toward diagnosing, treating, and preventing disease much earlier is the solution we need to relieve this pressure. Drawing on decades of leadership experience across Novartis, Biogen, UMass Memorial Health, and beyond, Ray explains why technology is now a strategic priority in healthcare, why culture matters just as much as data, and why solving chronic disease will require new thinking on the part of providers, payers, patients, and healthcare leaders alike. Healthcare systems all around the world are under pressure, and the common denominator is chronic disease. In this episode of Biology Matters, Ray Pawlicki, Executive Chairman at PrecisionLife, and host Steve Gardner explore how a shift from reacting to illness toward diagnosing, treating, and preventing disease much earlier is the solution we need to relieve this pressure. Drawing on decades of leadership experience across Novartis, Biogen, UMass Memorial Health, and beyond, Ray explains why technology is now a strategic priority in healthcare, why culture matters just as much as data, and why solving chronic disease will require new thinking on the part of providers, payers, patients, and healthcare leaders alike. Chronic disease, Precision medicine, Preventive healthcare, Early diagnosis, AI in healthcare, Healthcare innovation, Healthcare leadership, Chronic disease management, Personalized medicine, Health technology No No Why Biology Matters: The Future of Precision and Preventive Healthcare https://podcasts.fame.so/e/r874q21n-healthcare-fails-at-chronic-disease Why Biology Matters: The Future of Precision and Preventive Healthcare 0 No No k08yxpr1 Healthcare systems around the world are under growing pressure from aging populations, rising costs, and the increasing burden of chronic disease. In the debut episode of Biology Matters, hosts Steve and Rowan Gardner, co-founders of PrecisionLife, explore why many complex diseases remain so difficult to understand and treat and the merit in answering the question, “How do we prevent people from falling sick? ”. This conversation reveals how advances in biology, data, and precision medicine could help healthcare move toward earlier prediction, more personalized treatment, and better prevention because building healthier futures demands that science, healthcare, and society completely rethink how we understand disease. Healthcare systems around the world are under growing pressure from aging populations, rising costs and the increasing burden of chronic disease. In the debut episode of Biology Matters, hosts Steve and Rowan Gardner, co-founders of PrecisionLife, explore why many complex diseases remain so difficult to understand and treat and the importance of answering the question “How do we prevent people from falling sick?”.

What You'll Learn:

Why the Human Genome Project succeeded in cancer but stalled in chronic disease
How to reframe chronic disease from a market problem to an economic opportunity
The critical infrastructure gap preventing precision medicine deployment in chronic disease
Why political and cultural incentives systematically favor treating symptoms over preventing disease
How leading health systems (UAE, Singapore, integrated US systems) are building competitive advantage through data governance
The immediate opportunity in women's health and rare conditions like ME/CFS and long COVID

Episode Resources:

Steve Gardner on LinkedIn
Rowan Gardner on LinkedIn
PrecisionLife Website

Biology Matters is handcrafted by our friends over at: fame.so

]]> Wed, 17 Jun 2026 09:00:00 +0000 PrecisionLife PrecisionLife 2953 Healthcare systems around the world are under growing pressure from aging populations, rising costs, and the increasing burden of chronic disease. In the debut episode of Biology Matters, hosts Steve and Rowan Gardner, co-founders of PrecisionLife, explore why many complex diseases remain so difficult to understand and treat and the merit in answering the question, “How do we prevent people from falling sick? ”. This conversation reveals how advances in biology, data, and precision medicine could help healthcare move toward earlier prediction, more personalized treatment, and better prevention because building healthier futures demands that science, healthcare, and society completely rethink how we understand disease. Healthcare systems around the world are under growing pressure from aging populations, rising costs, and the increasing burden of chronic disease. In the debut episode of Biology Matters, hosts Steve and Rowan Gardner, co-founders of PrecisionLife, explore why many complex diseases remain so difficult to understand and treat and the merit in answering the question, “How do we prevent people from falling sick? ”. This conversation reveals how advances in biology, data, and precision medicine could help healthcare move toward earlier prediction, more personalized treatment, and better prevention because building healthier futures demands that science, healthcare, and society completely rethink how we understand disease. Precision Medicine, Chronic Disease Prevention, Preventative Healthcare, Personalized Medicine, Healthcare Innovation, Genomics in Healthcare, Mechanism-Based Biology, Chronic Disease Management, Predictive Healthcare, Precision Health SolutionsThat No No Biology Matters Trailer https://podcasts.fame.so/e/286qjyrn-biology-matters-trailer Biology Matters Trailer 0 No No j12r4wv1 Biology Matters is a podcast about one of the biggest challenges facing modern healthcare: chronic disease. These conditions affect billions of people, account for the majority of healthcare spending, and yet remain poorly understood, difficult to diagnose, and often ineffective to treat. The result is not just a scientific problem, but a system-wide healthcare crisis. Hosted by Steve and Rowan Gardner of PrecisionLife, the podcast takes a different approach - starting with biology. Through conversations with healthcare executives, researchers, biotech leaders and patient advocates, Biology Matters explores how a deeper, mechanism-based understanding of disease can transform how we predict risk, stratify patients, and make better clinical and development decisions. Each episode connects biological insight to real-world impact - from improving patient outcomes and reducing system inefficiencies, to enabling more successful clinical trials and more precise treatment strategies. If healthcare is to move from reactive treatment to predictive, preventative, and personalized care, it will require a fundamental shift in how we understand disease. This podcast is about what that shift looks like - and what it will take to make it happen. Biology Matters is a podcast about one of the biggest challenges facing modern healthcare: chronic disease. These conditions affect billions of people and account for the majority of healthcare spending, and yet remain poorly understood, difficult to diagnose, and often ineffective to treat. And the result is not just a scientific problem but a system-wide, society-wide healthcare crisis.

Hosted by Steven Gardner and Rowan Gardner of Precision Life, the podcast takes a different approach, starting with biology. Through conversations with healthcare executives, researchers, biotech leaders, and patient advocates, Biology Matters explores how a deeper, mechanism-based understanding of disease can transform how we predict risk, stratify patients, and make better clinical and development decisions.

Each episode connects biological insight to real-world impact, from improving patient outcomes and reducing system inefficiencies to enabling more successful clinical trials and more precise treatment strategies.

If healthcare is to move from reactive treatment when we are sick to predictive, preventive, and personalized care, it will take a fundamental shift in how we understand disease. This podcast is about what that shift looks like and what it will take to make it happen.

Biology Matters is handcrafted by our friends over at: fame.so

]]> Tue, 26 May 2026 17:11:00 +0000 PrecisionLife PrecisionLife 159 Biology Matters is a podcast about one of the biggest challenges facing modern healthcare: chronic disease. These conditions affect billions of people, account for the majority of healthcare spending, and yet remain poorly understood, difficult to diagnose, and often ineffective to treat. The result is not just a scientific problem, but a system-wide healthcare crisis. Hosted by Steve and Rowan Gardner of PrecisionLife, the podcast takes a different approach - starting with biology. Through conversations with healthcare executives, researchers, biotech leaders and patient advocates, Biology Matters explores how a deeper, mechanism-based understanding of disease can transform how we predict risk, stratify patients, and make better clinical and development decisions. Each episode connects biological insight to real-world impact - from improving patient outcomes and reducing system inefficiencies, to enabling more successful clinical trials and more precise treatment strategies. If healthcare is to move from reactive treatment to predictive, preventative, and personalized care, it will require a fundamental shift in how we understand disease. This podcast is about what that shift looks like - and what it will take to make it happen. Biology Matters is a podcast about one of the biggest challenges facing modern healthcare: chronic disease. These conditions affect billions of people, account for the majority of healthcare spending, and yet remain poorly understood, difficult to diagnose, and often ineffective to treat. The result is not just a scientific problem, but a system-wide healthcare crisis. Hosted by Steve and Rowan Gardner of PrecisionLife, the podcast takes a different approach - starting with biology. Through conversations with healthcare executives, researchers, biotech leaders and patient advocates, Biology Matters explores how a deeper, mechanism-based understanding of disease can transform how we predict risk, stratify patients, and make better clinical and development decisions. Each episode connects biological insight to real-world impact - from improving patient outcomes and reducing system inefficiencies, to enabling more successful clinical trials and more precise treatment strategies. If healthcare is to move from reactive treatment to predictive, preventative, and personalized care, it will require a fundamental shift in how we understand disease. This podcast is about what that shift looks like - and what it will take to make it happen. No No